Use the hyperlinks, where available to access additional clinical trial information.
Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
Gilead Sciences, Inc.
This is a randomised, open-label trial with two arms. In the Experimental Arm, participants will receive Sacituzumab Govitecan-hziy (SG). SG will be administered intravenously (via IV) at a dose of 10mg/kg on Days 1 and 8 of a 21-day cycle. In the Active Comparator Arm, participants will receive Docetaxel. Docetaxel will be administered via IV at a dose of 75mg/m^2 on Day 1 of a 21-day cycle.